Seres Therapeutics Inc. (NASDAQ: MCRB) announced preclinical data for SER-603, a live biotherapeutic candidate for inflammatory bowel disease, at Digestive ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA